Concepts (206)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 18 | 2022 | 983 | 4.700 |
Why?
|
| Renin-Angiotensin System | 15 | 2021 | 178 | 4.180 |
Why?
|
| Coronavirus Infections | 11 | 2020 | 98 | 3.170 |
Why?
|
| Pneumonia, Viral | 11 | 2020 | 102 | 3.170 |
Why?
|
| Peptidyl-Dipeptidase A | 6 | 2020 | 132 | 2.130 |
Why?
|
| Premature Birth | 5 | 2022 | 72 | 2.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2021 | 136 | 1.990 |
Why?
|
| Fetal Growth Retardation | 3 | 2022 | 34 | 1.480 |
Why?
|
| Peptide Fragments | 6 | 2021 | 410 | 1.290 |
Why?
|
| Kidney | 5 | 2022 | 523 | 1.220 |
Why?
|
| Cardiovascular Diseases | 4 | 2022 | 1153 | 1.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2019 | 90 | 1.150 |
Why?
|
| Adolescent | 16 | 2022 | 3647 | 1.100 |
Why?
|
| Humans | 47 | 2022 | 33035 | 1.040 |
Why?
|
| Infant, Premature | 4 | 2019 | 70 | 0.970 |
Why?
|
| Child | 11 | 2022 | 2479 | 0.950 |
Why?
|
| Angiotensin I | 5 | 2021 | 241 | 0.930 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 121 | 0.900 |
Why?
|
| Graft Rejection | 2 | 2017 | 241 | 0.890 |
Why?
|
| Pregnancy | 8 | 2022 | 981 | 0.880 |
Why?
|
| Blood Pressure | 6 | 2022 | 867 | 0.810 |
Why?
|
| Female | 25 | 2022 | 20413 | 0.770 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2022 | 4 | 0.750 |
Why?
|
| Infant, Very Low Birth Weight | 6 | 2019 | 49 | 0.740 |
Why?
|
| Male | 24 | 2022 | 19789 | 0.730 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 512 | 0.720 |
Why?
|
| Pre-Eclampsia | 1 | 2022 | 66 | 0.720 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 13 | 0.700 |
Why?
|
| Hypophosphatemia | 1 | 2021 | 5 | 0.690 |
Why?
|
| Disease Progression | 2 | 2020 | 599 | 0.680 |
Why?
|
| Infant, Newborn | 9 | 2022 | 694 | 0.680 |
Why?
|
| Purpura, Schoenlein-Henoch | 1 | 2019 | 2 | 0.610 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 163 | 0.610 |
Why?
|
| Continental Population Groups | 2 | 2019 | 236 | 0.600 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 298 | 0.590 |
Why?
|
| Food Supply | 1 | 2019 | 67 | 0.570 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 17 | 0.570 |
Why?
|
| Fetus | 1 | 2019 | 86 | 0.570 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 88 | 0.570 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 84 | 0.560 |
Why?
|
| Nutrition Surveys | 1 | 2019 | 151 | 0.550 |
Why?
|
| Health Status Disparities | 1 | 2019 | 134 | 0.540 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 1590 | 0.540 |
Why?
|
| Child Behavior | 1 | 2017 | 24 | 0.540 |
Why?
|
| Complement C4b | 1 | 2017 | 2 | 0.540 |
Why?
|
| Nutritional Status | 1 | 2017 | 78 | 0.520 |
Why?
|
| Child, Preschool | 5 | 2022 | 1282 | 0.500 |
Why?
|
| Overweight | 1 | 2018 | 263 | 0.500 |
Why?
|
| Dietary Supplements | 1 | 2017 | 187 | 0.490 |
Why?
|
| Kidney Neoplasms | 1 | 2018 | 205 | 0.490 |
Why?
|
| Creatinine | 3 | 2022 | 199 | 0.490 |
Why?
|
| Hyperpigmentation | 1 | 2016 | 17 | 0.470 |
Why?
|
| Erythema | 1 | 2016 | 25 | 0.470 |
Why?
|
| Peritoneal Dialysis | 1 | 2016 | 25 | 0.470 |
Why?
|
| Hot Temperature | 1 | 2016 | 78 | 0.460 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2015 | 7 | 0.460 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 26 | 0.460 |
Why?
|
| Isoantibodies | 1 | 2015 | 12 | 0.460 |
Why?
|
| Transplants | 1 | 2015 | 23 | 0.460 |
Why?
|
| HLA Antigens | 1 | 2015 | 41 | 0.450 |
Why?
|
| Donor Selection | 1 | 2015 | 36 | 0.450 |
Why?
|
| Angiotensin II | 4 | 2021 | 245 | 0.430 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 355 | 0.420 |
Why?
|
| Retrospective Studies | 10 | 2022 | 3710 | 0.400 |
Why?
|
| Pain | 1 | 2016 | 301 | 0.400 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2290 | 0.390 |
Why?
|
| Sex Factors | 3 | 2019 | 686 | 0.370 |
Why?
|
| Nephrology | 2 | 2022 | 33 | 0.360 |
Why?
|
| Electronic Health Records | 3 | 2022 | 182 | 0.350 |
Why?
|
| Virus Internalization | 2 | 2020 | 7 | 0.320 |
Why?
|
| Risk Factors | 6 | 2021 | 4015 | 0.320 |
Why?
|
| Obesity | 1 | 2017 | 1182 | 0.310 |
Why?
|
| Renin | 2 | 2021 | 109 | 0.280 |
Why?
|
| Case-Control Studies | 2 | 2022 | 880 | 0.280 |
Why?
|
| Renal Dialysis | 2 | 2018 | 280 | 0.230 |
Why?
|
| Body Mass Index | 2 | 2018 | 912 | 0.230 |
Why?
|
| Prospective Studies | 2 | 2022 | 2343 | 0.220 |
Why?
|
| Sodium | 2 | 2021 | 42 | 0.220 |
Why?
|
| Potassium | 2 | 2021 | 40 | 0.210 |
Why?
|
| Comorbidity | 3 | 2020 | 573 | 0.210 |
Why?
|
| Blood Pressure Determination | 2 | 2020 | 103 | 0.180 |
Why?
|
| Losartan | 1 | 2022 | 64 | 0.180 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2022 | 65 | 0.180 |
Why?
|
| Aldosterone | 1 | 2021 | 27 | 0.180 |
Why?
|
| PHEX Phosphate Regulating Neutral Endopeptidase | 1 | 2021 | 3 | 0.170 |
Why?
|
| Lung Injury | 1 | 2022 | 67 | 0.170 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 17 | 0.170 |
Why?
|
| Health Personnel | 1 | 2022 | 131 | 0.170 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 10 | 0.170 |
Why?
|
| Medical History Taking | 1 | 2020 | 39 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 152 | 0.160 |
Why?
|
| Receptors, Virus | 1 | 2020 | 15 | 0.160 |
Why?
|
| Data Collection | 1 | 2021 | 185 | 0.160 |
Why?
|
| Electrolytes | 1 | 2020 | 11 | 0.160 |
Why?
|
| Pediatrics | 1 | 2022 | 156 | 0.160 |
Why?
|
| Tunica Intima | 1 | 2020 | 57 | 0.160 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 37 | 0.160 |
Why?
|
| Prognosis | 3 | 2020 | 1550 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2020 | 1470 | 0.160 |
Why?
|
| Rats, Inbred Lew | 1 | 2020 | 120 | 0.160 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 31 | 0.160 |
Why?
|
| Vitamin D | 1 | 2021 | 189 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2020 | 76 | 0.150 |
Why?
|
| Saliva | 1 | 2019 | 39 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2021 | 566 | 0.150 |
Why?
|
| Hydrocortisone | 1 | 2019 | 57 | 0.150 |
Why?
|
| Linear Models | 2 | 2017 | 446 | 0.150 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 19 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 241 | 0.150 |
Why?
|
| Proteinuria | 1 | 2019 | 55 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 682 | 0.150 |
Why?
|
| Algorithms | 1 | 2022 | 518 | 0.150 |
Why?
|
| Family Characteristics | 1 | 2019 | 37 | 0.150 |
Why?
|
| Prenatal Care | 1 | 2019 | 54 | 0.150 |
Why?
|
| Hospitalization | 4 | 2022 | 495 | 0.140 |
Why?
|
| Physical Fitness | 1 | 2019 | 135 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2017 | 3462 | 0.140 |
Why?
|
| Cardiovascular System | 1 | 2019 | 47 | 0.140 |
Why?
|
| Infant | 2 | 2022 | 1083 | 0.140 |
Why?
|
| Logistic Models | 2 | 2017 | 785 | 0.140 |
Why?
|
| Angiotensins | 1 | 2018 | 42 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 576 | 0.140 |
Why?
|
| Placenta | 1 | 2019 | 75 | 0.140 |
Why?
|
| Animals | 2 | 2020 | 7602 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 193 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2018 | 57 | 0.140 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2018 | 28 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 436 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 310 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 18 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2022 | 1855 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 897 | 0.130 |
Why?
|
| Hospital Mortality | 1 | 2018 | 205 | 0.130 |
Why?
|
| Fetal Organ Maturity | 1 | 2016 | 7 | 0.130 |
Why?
|
| United States | 3 | 2022 | 4137 | 0.120 |
Why?
|
| Biopsy | 1 | 2017 | 245 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 290 | 0.120 |
Why?
|
| Gestational Age | 3 | 2022 | 129 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2018 | 382 | 0.120 |
Why?
|
| Rats | 1 | 2020 | 1610 | 0.120 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 14 | 0.120 |
Why?
|
| Complement Pathway, Classical | 1 | 2015 | 2 | 0.120 |
Why?
|
| Complement C1q | 1 | 2015 | 4 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2019 | 689 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 785 | 0.110 |
Why?
|
| Young Adult | 1 | 2022 | 2749 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 457 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2015 | 186 | 0.110 |
Why?
|
| Exercise | 1 | 2019 | 690 | 0.110 |
Why?
|
| North Carolina | 1 | 2018 | 1550 | 0.100 |
Why?
|
| Graft Survival | 1 | 2015 | 313 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2015 | 207 | 0.100 |
Why?
|
| Adult | 2 | 2022 | 9607 | 0.090 |
Why?
|
| Brain | 1 | 2019 | 949 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 543 | 0.090 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2022 | 33 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 765 | 0.080 |
Why?
|
| Exercise Test | 2 | 2019 | 226 | 0.070 |
Why?
|
| Birth Weight | 2 | 2019 | 49 | 0.070 |
Why?
|
| Survival Rate | 2 | 2021 | 896 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 1253 | 0.060 |
Why?
|
| Privacy | 1 | 2022 | 10 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2022 | 29 | 0.050 |
Why?
|
| Documentation | 1 | 2022 | 47 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 100 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 486 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 2021 | 10 | 0.040 |
Why?
|
| Propensity Score | 1 | 2021 | 48 | 0.040 |
Why?
|
| Chromatography, Agarose | 1 | 2021 | 5 | 0.040 |
Why?
|
| Radioimmunoassay | 1 | 2021 | 23 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 147 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 32 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 31 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 205 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 546 | 0.040 |
Why?
|
| China | 1 | 2020 | 54 | 0.040 |
Why?
|
| Veterans | 1 | 2021 | 69 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 14 | 0.040 |
Why?
|
| Chlorides | 1 | 2020 | 13 | 0.040 |
Why?
|
| Publishing | 1 | 2021 | 62 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2020 | 16 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 65 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 107 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 193 | 0.040 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2019 | 108 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 90 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 775 | 0.040 |
Why?
|
| Lung | 1 | 2020 | 268 | 0.040 |
Why?
|
| Research Design | 1 | 2020 | 334 | 0.040 |
Why?
|
| Intensive Care, Neonatal | 1 | 2018 | 9 | 0.040 |
Why?
|
| Aged | 2 | 2022 | 10659 | 0.030 |
Why?
|
| Calcium | 1 | 2020 | 323 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 412 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2017 | 32 | 0.030 |
Why?
|
| Middle Aged | 2 | 2022 | 12229 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1003 | 0.030 |
Why?
|
| Uric Acid | 1 | 2017 | 28 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 885 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 369 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1204 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 243 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 468 | 0.030 |
Why?
|
| Cholesterol | 1 | 2017 | 255 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2019 | 1163 | 0.030 |
Why?
|
| Body Composition | 1 | 2017 | 391 | 0.030 |
Why?
|
| African Americans | 1 | 2019 | 1425 | 0.020 |
Why?
|